Bank of Montreal Can Sells 49,214 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Bank of Montreal Can reduced its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 71.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,447 shares of the specialty pharmaceutical company’s stock after selling 49,214 shares during the period. Bank of Montreal Can’s holdings in Jazz Pharmaceuticals were worth $2,157,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its stake in Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 97 shares during the period. GAMMA Investing LLC boosted its position in shares of Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares in the last quarter. Arizona State Retirement System raised its holdings in Jazz Pharmaceuticals by 0.8% in the second quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock worth $1,770,000 after purchasing an additional 130 shares in the last quarter. Waterfront Wealth Inc. lifted its position in Jazz Pharmaceuticals by 2.5% during the second quarter. Waterfront Wealth Inc. now owns 9,411 shares of the specialty pharmaceutical company’s stock valued at $1,004,000 after buying an additional 230 shares during the period. Finally, Tectonic Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 6.3% during the 3rd quarter. Tectonic Advisors LLC now owns 3,891 shares of the specialty pharmaceutical company’s stock valued at $433,000 after buying an additional 232 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on JAZZ shares. JPMorgan Chase & Co. increased their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research note on Monday, August 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Piper Sandler reissued an “overweight” rating and issued a $163.00 price target (down from $166.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, November 21st. Robert W. Baird upped their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Finally, Royal Bank of Canada boosted their target price on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday, October 23rd. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $175.33.

Insider Activity

In related news, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 2,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $121.17, for a total value of $242,340.00. Following the sale, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at $51,742,619.25. This represents a 0.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,753 shares of company stock valued at $816,289 in the last ninety days. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Trading Down 0.3 %

Shares of JAZZ stock opened at $123.14 on Friday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.17. The stock has a market capitalization of $7.45 billion, a P/E ratio of 17.34, a P/E/G ratio of 1.03 and a beta of 0.57. The firm’s 50 day moving average is $115.95 and its 200 day moving average is $111.46.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.